LTP Financials: Results, Ratios & Statements | Ltr Pharma

LTP

Ltr Pharma

Pharmaceuticals, Biotechnology & Life Sciences

LTR Pharma is an Australian drug development company focused on men's health, specifically commercializing a rapid-onset, on-demand therapeutic nasal spray for erectile dysfunction. Their lead product, SPONTAN®, utilizes intranasal delivery technology of a PDE5 inhibitor, aiming for faster action and improved spontaneity compared to existing ED therapies.

Short position

short percentage0.08%

reported shorts147.8K

shares on issue182.275M

Ltr Pharma (ASX:LTP) has 0.08% of its shares on issue reported as short positions as of 5 Oct 2026, or about 147,793 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.53% in July 2024. LTP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue: $1.6M (source: ASX (Markit))vs $145.8K (FY25); ASX (Markit), as at 29 Sep 2026
NPAT: −$14.2M (source: ASX (Markit))vs −$5.6M (FY25); ASX (Markit), as at 29 Sep 2026
EPS (diluted): −$0.078 (source: Derived: trailing 12 months at year end)vs −$0.033 (FY25); Derived: trailing 12 months at year end, as at 29 Sep 2026

Rev YoY: n/mFY
EPS YoY: n/aTTM

ASX (Markit)
Derived: trailing 12 months at year end

Key ratios

Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026

Gross margin: 11.4%
Operating margin: −896.8%
Net margin: −874.1%
FCF margin: −669.3%
ROE: n/a
ROA: n/a
FCF conversion: n/a
Net debt (excl. leases): n/a
Net debt / EBITDA: n/a
Current ratio: n/a
Interest cover: −41,638.9×
Cash dividends paid / net profit: n/a
Market cap: n/a (no share count we can vouch for)
P/E: n/a
P/B: n/a (no share count we can vouch for)

Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 29 Sep 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

LTP income, newest period first, figures in AUD
Line item	FY26	FY25	FY24	FY23
Revenue	$1.6M (source: ASX (Markit))	$145.8K	$49.3K (source: ASX (Markit))	$90 (source: ASX (Markit))
Gross profit	$183.9K (source: Derived: trailing 12 months at year end)	$145.8K	n/a	n/a
Operating income	−$14.5M (source: Derived: trailing 12 months at year end)	−$7.5M	−$7.0M	n/a
EBITDA	−$14.2M (source: Derived: trailing 12 months at year end)	−$5.6M	−$7.0M	n/a
EBIT	−$14.2M (source: Derived: trailing 12 months at year end)	−$5.6M	−$7.0M	n/a
Interest expense	$349 (source: Derived: trailing 12 months at year end)	$23	$422	n/a
Pretax income	−$14.2M (source: Derived: trailing 12 months at year end)	−$5.6M	−$7.0M	n/a
Tax	$0 (source: Derived: trailing 12 months at year end)	$0	$0	n/a
NPAT	−$14.2M (source: ASX (Markit))	−$5.6M	−$7.0M	−$1.5M (source: ASX (Markit))
Net interest income	$896.1K (source: Derived: trailing 12 months at year end)	$595.2K	−$93	n/a
EPS basic	−$0.078 (source: Derived: trailing 12 months at year end)	−$0.033	−$0.050	−$0.010
EPS diluted	−$0.078 (source: Derived: trailing 12 months at year end)	−$0.033	−$0.050	−$0.010
Shares	n/a	181.0M	139.4M	139.4M

ASX (Markit)
Derived: trailing 12 months at year end

Financial reports

The company's own filings, newest first

Showing 10 of 28 reports